BioPharma Dive September 4, 2024
The Series C financing is the most lucrative secured by any gene and cell therapy developer in 2024, according to BioPharma Dive data.
Dive Brief:
- Arsenal Biosciences on Wednesday said it has raised $325 million in one of the largest private funding rounds for a biotechnology startup this year, bucking a slump in venture investment into cell and gene therapy developers.
- The Series C round will help the California company develop experimental cancer cell therapies. Among them are a pair of ovarian and kidney cancer treatments currently in early-stage testing, as well as additional research ArsenalBio is advancing via collaborations with Bristol Myers Squibb and Roche.
- ArsenalBio has now secured $700 million in equity funding and partnership dollars since...
Today's Sponsors
Today's Sponsor